However, the median OS with this regimen is still only 22 months . Recently, Conroy et al. demonstrated a significant survival benefit with modified FOLFIRINOX compared to gemcitabine alone (PRODIGE-24 trial) in highly selected patients . In addition, new chemotherapeutic strategies in combination with gemcitabine are currently explored and also improved the prognosis of pancreatic cancer [4, 5]. Read more . . .
Pancreatic cancer is a highly malignant disease, with an estimated 5-years survival of 9% . At diagnosis, approximately 15% of the patients have resectable disease (stage I or II), which indicates surgery followed by systemic therapy . The CONKO-001 trial is the first randomized controlled trial in pancreatic cancer that reported longer overall survival (OS) rates in patients treated with adjuvant gemcitabine compared with observation alone.